Jonathan W.
Betts
a,
Lynette M.
Phee
ab,
Muhd H. F.
Abdul Momin
a,
Klaus-Daniel
Umland
c,
Jurgen
Brem
c,
Christopher J.
Schofield
c and
David W.
Wareham
*ab
aAntimicrobial Research Group, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK. E-mail: d.w.wareham@qmul.ac.uk
bDivision of Infection, Barts Health NHS Trust, London, E1 1BB, UK
cDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK
First published on 16th November 2015
The thioenol ML302F was recently identified as an inhibitor of class B metallo-β-lactamases (MBLs). We assessed the activity of ML302F when combined with meropenem (MEM) against 31 carbapenem resistant Gram-negative clinical isolates. Minimum inhibitory concentrations of MEM:
ML302F were determined at fixed ratios of 1
:
4 and 1
:
8 using strains producing variants of the clinically relevant VIM-like MBL. Toxicity and efficacy in vivo was assessed in a Galleria mellonella invertebrate model against strains producing VIM-1, VIM-2 and VIM-4 variants. At a fixed MEM
:
ML302F ratio of 1
:
8, 22/31 isolates were rendered either susceptible (MIC ≤ 2 mg L−1), or intermediate (MIC 4–8 mg L−1) to MEM. ML302F alone was not toxic at up to 80 mg kg−1 in G. mellonella and treatment with MEM 0.6 mg kg−1
:
ML302F 4.8 mg kg−1 significantly improved the survival of infected larvae. As ML302F was able to successfully restore susceptibility to resistant strains both in vitro and in vivo it represents a structurally interesting inhibitor in the search for new MBL inhibitors.
The rhodanine ML302 was initially identified as a MBL inhibitor in a high throughput screen and subsequently characterised as a non-competitive inhibitor of class B (IMP, VIM, NDM) metallo-β-lactamases in vitro.4 Recently the mechanism behind the apparent inhibition by ML302 was investigated in crystallographic, NMR, and kinetic studies. These, unexpectedly revealed that ML302 undergoes hydrolysis, to generate the thioenol ML302F (Fig. 1). The thiol of ML302F chelates the two zinc ions present in the active site of most MBLs in a manner mimicking an intermediate in β-lactam hydrolysis.5 In some cases the observed inhibition of MBLs by ML302/ML302F combinations may involve ternary complexes. In some instances ML302F is able to inhibit the carbapenemase activity of MBLs at low μM concentrations (IC50 VIM-2 0.30 μM) sufficient to restore the activity of meropenem against MBL-producing strains.5
![]() | ||
Fig. 1 Structures of (a) the thioenol ML302F, (b) the ‘parent’ rhodanine ML302, (c) outline mechanism for MBL catalysed β-lactam hydrolysis as exemplified with meropenem (PDB ID: 4EYL), and (d) cartoons based on a crystal structure of ML302F (PDB ID: 4PVO) complexed with MBLs showing how the inhibitor mimics an enzyme-intermediate/product complex. |
Neither ML302 nor ML302F have significant cytotoxicity towards eukaryotic cells in tissue culture (>100 μM) but have not yet been assessed in any animal model of antimicrobial therapeutics. The wax moth caterpillar Galleria mellonella is increasingly being used as a simple invertebrate model for pre-clinical assessment of the efficacy, toxicity and pharmacokinetics of antimicrobials.6–9 Here we report studies on the activity of ML302F in combination with MEM against a collection of carbapenem resistant clinical isolates (Pseudomonas, Klebsiella, Enterobacter, Escherichia coli, Providencia) producing clinically relevant variants of the VIM (VIM-1/2/4) MBL. Preferred ratios of MEM to ML302F required for synergy in vitro were determined and then used at a simulated humanized pharmacokinetic dose in the treatment of G. mellonella infected with carbapenem resistant P. aeruginosa, K. pneumoniae and E. coli.
Thirty strains were either resistant (MIC > 8 mg L−1) or had reduced susceptibility (MIC ≥ 4 mg L−1) to MEM alone as judged by the European Committee on Antimicrobial Susceptibility (EUCAST) breakpoint criteria. One K. pneumoniae isolate harbouring blaVIM-1 was deemed susceptible (MIC 1 mg L−1). ML302F had no antimicrobial activity alone at concentrations up to 512 mg L−1.
Using a fixed 1:
8 ratio of MEM
:
ML302F in vitro susceptibility to carbapenems was increased in 22/31 (70%) of the isolates with 11 rendered susceptible (MIC ≤ 2 mg L−1) or intermediate (MIC 4–8 mg L−1). For 9 isolates, the MIC of MEM remained >8 mg L−1 (Table 1).
MBL | Isolate | MIC (mg L−1) | FICI | |
---|---|---|---|---|
MEM | MEM + ML302F | |||
VIM-1 | K. pneumoniae GR54 | 128 | 4 | 0.09 |
VIM-1 | K. pneumoniae 177 | 1 | 1 | 1.02 |
VIM-1 | P. stuartii 67 | 8 | 1 | 0.14 |
VIM-1 | P. stuartii 70 | 8 | 1 | 0.14 |
VIM-2 | P. aeruginosa 30 | 64 | 8 | 0.25 |
VIM-2 | P. aeruginosa 47 | 32 | 1 | 0.05 |
VIM-2 | P. aeruginosa 50 | 32 | 8 | 0.38 |
VIM-2 | P. aeruginosa GR57 | 32 | 4 | 0.19 |
VIM-2 | P. aeruginosa GR58 | 32 | 8 | 0.38 |
VIM-2 | P. aeruginosa GR62 | 32 | 8 | 0.38 |
VIM-2 | P. aeruginosa GR64 | 32 | 4 | 0.19 |
VIM-2 | P. aeruginosa 3 (13) | 64 | 8 | 0.25 |
VIM-2 | P. aeruginosa 8 (13) | 128 | 16 | 0.38 |
VIM-2 | P. aeruginosa 9 (13) | 128 | 16 | 0.38 |
VIM-2 | P. aeruginosa 11 (13) | 32 | 2 | 0.09 |
VIM-2 | P. aeruginosa 6 (14) | 128 | 16 | 0.38 |
VIM-2 | P. aeruginosa 11 (14) | 128 | 32 | 0.75 |
VIM-2 | P. aeruginosa 12 (14) | 128 | 32 | 0.75 |
VIM-2 | P. aeruginosa 13 (14) | 32 | 16 | 0.75 |
VIM-2 | P. aeruginosa 14 (14) | 64 | 2 | 0.06 |
VIM-2 | P. aeruginosa 15 (14) | 64 | 16 | 0.5 |
VIM-2 | P. aeruginosa 16 (14) | 64 | 16 | 0.5 |
VIM-2 | P. aeruginosa 27 (14) | 64 | 16 | 0.5 |
VIM-4 | E. cloacae 102 | 32 | 4 | 0.19 |
VIM-4 | E. coli 98 | 16 | 2 | 0.16 |
VIM-4 | K. oxytoca 95 | 32 | 8 | 0.38 |
VIM-4 | K. oxytoca 126 | 32 | 4 | 0.19 |
VIM-4 | K. pneumoniae 101 | 32 | 2 | 0.09 |
VIM-4 | K. pneumoniae 120 | 16 | 2 | 0.25 |
VIM-4 | K. pneumoniae 128 | 4 | 1 | 0.27 |
VIM-4 | K. pneumoniae 196 | 16 | 1 | 0.08 |
ML302F was non-toxic when administered to G. mellonella by injection at doses up to 80 mg kg−1 (100% survival of all larvae at 96 h). The inoculum required for staggered killing of >50% of larvae by carbapenem resistant strains over 96 h varied by species. The LD50 was <101, 105 and 104 CFU per larvae for P. aeruginosa GR57, E. coli 98 and K. pneumoniae respectively.
In treatment assays, survival of ML302F (4.8 mg kg−1) treated larvae was similar to those given PBS for the treatment of PA GR57, EC 98 and KP 120 infections. Monotherapy with MEM (0.6 mg kg−1) was superior to either PBS and ML302F (P < 0.0001), but the % survival was only 44%, 23% and 69% versus strains EC 98, PA GR57 and KP 120, respectively. The addition of ML302F to MEM significantly improved the survival of infected larva (P < 0.0001) compared to MEM alone, with survival rates of 69% (EC 98), 81% (PA GR57) and 98% (KP 120) at 96 (Fig. 2) and a relative risk for MEM-ML302F versus MEM of 0.64, 0.28 and 0.70 for these isolates.
The activity of ML302F in combination with MEM was assessed in checkerboard assays with fractional inhibitory concentration index (FICI) and MEM:
ML302F ratio used to quantify interactions.10 A FICI (MIC of MEM/ML302F + MIC ML302F/MEM) of ≤0.5 was defined as synergy, a FICI of 0.5 to 4.0 as indifferent or additive, and values of >4.0 as antagonistic. MICs for the MEM/ML302F combination strains studied were determined at fixed MEM
:
ML302F ratios of 1
:
4 and 1
:
8 by BMD.
Larvae were scored for survival over 96 h and kill curves analysed by the log-rank test for trend. Relative risk (RR) of survival between the different treatment arms was calculated using Fisher's exact test with, two-tailed P-values of <0.05 considered statistically significant.
This journal is © The Royal Society of Chemistry 2016 |